GSK plc
GLAXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $31,376 | $30,328 | $29,324 | $34,114 |
| % Growth | 3.5% | 3.4% | -14% | – |
| Cost of Goods Sold | $9,048 | $8,565 | $9,554 | $11,603 |
| Gross Profit | $22,328 | $21,763 | $19,770 | $22,511 |
| % Margin | 71.2% | 71.8% | 67.4% | 66% |
| R&D Expenses | $6,401 | $6,223 | $5,488 | $5,278 |
| G&A Expenses | $11,015 | $9,385 | $8,372 | $10,975 |
| SG&A Expenses | $11,015 | $9,385 | $8,372 | $10,975 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $891 | -$590 | $0 | $0 |
| Operating Expenses | $18,307 | $15,018 | $13,337 | $16,310 |
| Operating Income | $4,021 | $6,745 | $6,433 | $6,201 |
| % Margin | 12.8% | 22.2% | 21.9% | 18.2% |
| Other Income/Exp. Net | -$544 | -$681 | -$805 | -$2,339 |
| Pre-Tax Income | $3,477 | $6,064 | $5,628 | $3,862 |
| Tax Expense | $526 | $756 | $707 | $346 |
| Net Income | $2,575 | $4,928 | $14,956 | $4,385 |
| % Margin | 8.2% | 16.2% | 51% | 12.9% |
| EPS | 0.63 | 1.2 | 3.71 | 1.37 |
| % Growth | -47.5% | -67.7% | 170.8% | – |
| EPS Diluted | 0.62 | 1.2 | 3.66 | 1.35 |
| Weighted Avg Shares Out | 4,080 | 4,110 | 4,026 | 3,202 |
| Weighted Avg Shares Out Dil | 4,142 | 4,111 | 4,084 | 3,242 |
| Supplemental Information | – | – | – | – |
| Interest Income | $60 | $48 | $76 | $28 |
| Interest Expense | $640 | $775 | $879 | $784 |
| Depreciation & Amortization | $2,551 | $2,294 | $2,147 | $2,122 |
| EBITDA | $6,668 | $9,083 | $8,601 | $6,485 |
| % Margin | 21.3% | 29.9% | 29.3% | 19% |